Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8661934 | International Journal of Cardiology | 2018 | 30 Pages |
Abstract
A common clinical dilemma regarding treatment of patients with a mechanical valve is the need for concomitant antiplatelet therapy for a variety of reasons, referred to as triple therapy. Triple therapy is when a patient is prescribed aspirin, a P2Y12 antagonist, and an oral anticoagulant. Based on the totality of the available evidence, best practice in 2017 for patients with mechanical valves undergoing percutaneous coronary intervention (PCI) is unclear. Furthermore, the optimal duration of dual antiplatelet therapy after PCI is evolving. With better valve designs that are less thrombogenic, the thromboembolic risks can be reduced at a lower international normalized ratio target, thus decreasing the bleeding risk. This review will offer an in-depth survey of current guidelines, current evidence, suggested approach for PCI in this cohort, and future studies regarding mechanical valve patients undergoing PCI.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Deepakraj Gajanana, Toby Rogers, Micaela Iantorno, Kyle D. Buchanan, Itsik Ben-Dor, Augusto D. Pichard, Lowell F. Satler, Rebecca Torguson, Petros G. Okubagzi, Ron Waksman,